Dihydropyrimidine dehydrogenase mRNA expression in peripheral blood of rectal cancer patients is significantly associated with residual tumor and distant metastases following resection

Hoffmann, Andreas-Claudius; Brabender, Jan; Metzger, Ralf; Ling, Frederike C.; Warnecke-Eberz, Ute; Lurje, Georg; Hoelscher, Arnulf H.; Schneider, Paul M.; Vallböhmer, Daniel

doi:10.1002/jso.21233

Cited by 3 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, no ideal method is currently available and several limitations apply to each of the following methods described. Some of them however may be overcome if they are used in combination [25, 30–33]. The most common techniques for CTC enrichment and detection are discussed as follows (Table 1).…”

Section: Methodological Considerations For the Detection Of Ctcsmentioning

confidence: 99%

“…CTCs have been studied in colorectal cancer (CRC) [30, 66] and recent studies have shown their clinical utility in patients with metastatic CRC [33, 67]. In a prospective multicenter clinical trial, 430 patients beginning a new first-, second-, or third-line systemic therapy had peripheral blood obtained for enumeration of CTCs (CellSearch, Veridex LLC, Raritan, NJ, USA) at baseline (pretreatment) and subsequent time points.…”

Section: Clinical Implications Of Ctcs In Gastrointestinal Malignamentioning

confidence: 99%

See 1 more Smart Citation

Circulating Tumor Cells in Gastrointestinal Malignancies: Current Techniques and Clinical Implications

Lurje

Schiesser

Claudius

et al. 2010

Journal of Oncology

Self Cite

View full text Add to dashboard Cite

Since their introduction more than 50 years by Engell, circulating tumor cells (CTCs) have been evaluated in cancer patients and their detection has been correlated with clinical outcome, in esophageal, gastric, and colorectal cancer. With the availability of refined technologies, the identification of CTCs from peripheral blood is emerging as a useful tool for the detection of malignancy, monitoring disease progression, and measuring response to therapy. However, increasing evidence suggests a variety of factors to be responsible for disease progression. The analysis of a single CTC marker is therefore unlikely to accurately predict progression of disease with sufficient resolution and reproducibility. Here we discuss the current concept of CTCs, summarize the available techniques for their detection and characterization, and aim to provide a comprehensive update on the clinical implications of CTCs in gastrointestinal (GI) malignancies.

show abstract

Section: Methodological Considerations For the Detection Of Ctcsmentioning

confidence: 99%